康聖環球(09960.HK)2022年總收入同比增加49.0%至13.87億元
格隆匯3月27日丨康聖環球(09960.HK)公吿，截至2022年12月31日止年度業績，公司的總收入同比增加49.0%至人民幣13.87億元；母公司擁有人應占年內利潤7545.7萬元，去年則虧損14.54億元，扭虧為盈；母公司普通權益持有人應占每股盈利9.49分。
總收入同比增加原因是以下因素的綜合影響：(i)因新冠防控政策，全民篩查需求帶來的收入增加；(ii)面對新冠疫情帶來的持續負面影響，公司憑藉檢測產品的迭代，客户羣體的擴展，穩定了公司在血液學、神經學等專科檢測；及(iii)由於新冠疫情帶來的各種負面因素仍在影響公司的特檢業務，一些地方的封鎖，導致公司特檢業務的增速受到比較大的影響。
截至2022年12月31日止年度，公司的血液學檢測服務收入為人民幣5.26億元，較2021年保持穩定。從區域收入看，2022年度，上海、北京、東北及新疆等地受疫情影響較大，西南地區尤其是四川地區受疫情影響相對較小。
2022年，公司新增產品及產品組合約100項，其中淋巴瘤363種基因突變檢測基因組脱氧核糖核酸(gDNA)項目的檢測量同比增長142.6%，髓系血液疾病248種基因突變檢測項目的檢測量實現月均3倍增長，新推出的CAR-T伴隨診斷產品組合也獲得臨牀專家高度認可。於報吿期內，公司新簽約合作醫院25家，與全國9家大中型教學醫院進行了共建合作及項目轉化合作。
截至2022年12月31日止年度，公司的神經學檢測服務收入為人民幣9540萬元，同比增加6.1%。公司的神經學檢測產品線現處於快速增長期。在成人神內檢測方面，公司推出(其中包括)自免腦大套餐(TBA)、症候羣項目、重症肌無力項目、靶向宏基因項目和認知障礙AD5項，涵蓋神經免疫、神經感染、藥物濃度、藥物基因和認知障礙方面。
兒童神內檢測方面，公司在完善兒童神內免疫及兒童神內感染項目的基礎上，重點突破兒童神內遺傳項目，新增RNA-seq和人類全基因組檢測項目。
於報吿期內，客户方面，公司積極進行拓展，新增合作醫院超30家。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
